Feel the Earth Move Under Your Brand?

| December 22, 2016

article image
It’s a new year with new forecasts, wise prognostications, and sage extrapolations informed by last year’s rear view mirror. They’re often insightful. Sometimes misguided. Always interesting. What many in our industry may overlook as they try to identify some new trend, however, are the changes that move below our feet. Biopharma industry tectonic plates, if you will. These are forces so powerful that they will continue to shift our business not just this year, but into the foreseeable future. They’re not all new, but they’re not going away. And they have the potential to disrupt even the most thoughtful marketing plans. So ignore them at your peril as you plan for 2016.

Spotlight

Indoco Remedies Ltd.

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Pharma Company with presence in 55 countries. Indoco, a USD 165 million company, employs over 6000 people including 300 skilled scientists. The Company has 9 manufacturing facilities, out of which 6 are for finished dosage forms and 3 for APIs, supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, SUKL-Czech Republic, TGA-Australia, JAZMP- Slovenia, MCC-South Africa, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya and FDA-Ghana.

OTHER ARTICLES

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | February 25, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | February 25, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | February 25, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Spotlight

Indoco Remedies Ltd.

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Pharma Company with presence in 55 countries. Indoco, a USD 165 million company, employs over 6000 people including 300 skilled scientists. The Company has 9 manufacturing facilities, out of which 6 are for finished dosage forms and 3 for APIs, supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, SUKL-Czech Republic, TGA-Australia, JAZMP- Slovenia, MCC-South Africa, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya and FDA-Ghana.

Events